Siegfried Holding Ltd (SFZN) - Total Assets
Based on the latest financial reports, Siegfried Holding Ltd (SFZN) holds total assets worth CHF1.97 Billion CHF (≈ $2.49 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Siegfried Holding Ltd for net asset value and shareholders' equity analysis.
Siegfried Holding Ltd - Total Assets Trend (2002–2024)
This chart illustrates how Siegfried Holding Ltd's total assets have evolved over time, based on quarterly financial data.
Siegfried Holding Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Siegfried Holding Ltd's total assets of CHF1.97 Billion consist of 48.6% current assets and 51.4% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF38.76 Million | 2.0% |
| Accounts Receivable | CHF411.39 Million | 21.3% |
| Inventory | CHF387.58 Million | 20.0% |
| Property, Plant & Equipment | CHF909.99 Million | 47.1% |
| Intangible Assets | CHF55.89 Million | 2.9% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how Siegfried Holding Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Siegfried Holding Ltd (SFZN) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Siegfried Holding Ltd's current assets represent 48.6% of total assets in 2024, an increase from 37.5% in 2002.
- Cash Position: Cash and equivalents constituted 2.0% of total assets in 2024, down from 5.4% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2002.
- Asset Diversification: The largest asset category is property, plant & equipment at 47.1% of total assets.
Siegfried Holding Ltd Competitors by Total Assets
Key competitors of Siegfried Holding Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Siegfried Holding Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.91 | 2.70 | 3.56 |
| Quick Ratio | 1.45 | 1.40 | 1.83 |
| Cash Ratio | 0.11 | 0.18 | 0.00 |
| Working Capital | CHF618.36 Million | CHF606.68 Million | CHF430.71 Million |
Siegfried Holding Ltd - Advanced Valuation Insights
This section examines the relationship between Siegfried Holding Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.83 |
| Latest Market Cap to Assets Ratio | 1.92 |
| Asset Growth Rate (YoY) | 3.9% |
| Total Assets | CHF1.93 Billion |
| Market Capitalization | $3.71 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Siegfried Holding Ltd's assets above their book value (1.92x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Siegfried Holding Ltd's assets grew by 3.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Siegfried Holding Ltd (2002–2024)
The table below shows the annual total assets of Siegfried Holding Ltd from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CHF1.93 Billion ≈ $2.44 Billion |
+3.88% |
| 2023-12-31 | CHF1.86 Billion ≈ $2.35 Billion |
+3.81% |
| 2022-12-31 | CHF1.79 Billion ≈ $2.27 Billion |
+7.43% |
| 2021-12-31 | CHF1.67 Billion ≈ $2.11 Billion |
+34.36% |
| 2020-12-31 | CHF1.24 Billion ≈ $1.57 Billion |
+6.29% |
| 2019-12-31 | CHF1.17 Billion ≈ $1.48 Billion |
+5.95% |
| 2018-12-31 | CHF1.10 Billion ≈ $1.39 Billion |
+3.00% |
| 2017-12-31 | CHF1.07 Billion ≈ $1.35 Billion |
+4.86% |
| 2016-12-31 | CHF1.02 Billion ≈ $1.29 Billion |
+1.74% |
| 2015-12-31 | CHF1.00 Billion ≈ $1.27 Billion |
+59.46% |
| 2014-12-31 | CHF629.57 Million ≈ $795.95 Million |
+17.07% |
| 2013-12-31 | CHF537.77 Million ≈ $679.89 Million |
+12.66% |
| 2012-12-31 | CHF477.36 Million ≈ $603.51 Million |
+6.55% |
| 2011-12-31 | CHF448.00 Million ≈ $566.39 Million |
-3.46% |
| 2010-12-31 | CHF464.05 Million ≈ $586.69 Million |
-2.73% |
| 2009-12-31 | CHF477.07 Million ≈ $603.14 Million |
-10.80% |
| 2008-12-31 | CHF534.81 Million ≈ $676.14 Million |
-18.81% |
| 2007-12-31 | CHF658.74 Million ≈ $832.82 Million |
-4.97% |
| 2006-12-31 | CHF693.20 Million ≈ $876.39 Million |
+2.31% |
| 2005-12-31 | CHF677.52 Million ≈ $856.57 Million |
+15.65% |
| 2004-12-31 | CHF585.82 Million ≈ $740.64 Million |
-9.16% |
| 2003-12-31 | CHF644.88 Million ≈ $815.30 Million |
+9.18% |
| 2002-12-31 | CHF590.67 Million ≈ $746.77 Million |
-- |
About Siegfried Holding Ltd
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. The company offers drug substances, including exclusive synthesis that manufactures custom APIs. It also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pa… Read more